Osteogenic differentiation or interferon-gamma pretreatment regulates immunological activities of human fetal bone marrow-derived Flk-1~+ mesenchymal stem cell
Bin Zhang,Liu Rui,Zhu Xi-shan,Xiaowei Dou,Liu Xing-xia,Yuan Chen,Zhao Chun-hua
2008-01-01
Abstract:BACKGROUND: Mesenchymal stem cells (MSCs) may differentiate into committed cells in the process of repairing allogenic tissue damage, and no rejection happens although the upregulation of major histocompatibility complex (MHC) and costimulatory molecules may induce the rejection in a theoretical manner. It is presumed that MSCs under allogenic tissue differentiation and inflammatory factor microenvironment are potential to differentiate into terminal cells with immunoregulatory activity and escape immune surveillance. OBJECTIVE: To utilize in vitro osteogenic differentiation and interferon-γpretreatment to simulate the microenvironment of differentiation and inflammation in vivo, and to explore whether human fetal bone marrow-derived Flk-1+ MSCs still remain their immunological activities. DESIGN, TIME AND SETTING: Controlled cytological observation in vitro was performed in School of Basic Medicine, Peking Union Medical College from September 2007 to May 2008. MATERIALS: Two bone marrow samples were taken from aborted fetus provided by Beijing Huilongguan Maternity Hospital, and peripheral blood samples from healthy volunteers aged 15-35 years recruited from Beijing 307 Hospital. Interferon-γ and such osteogenic inductor as dexamethasone, β-glycerophosphate and ascorbic acid were purchased from Sigma-Aldrich. METHODS: Fetal bone marrow mononuclear cells were isolated by means of Ficoll method, and cells above white circular layer were harvested and inoculated at a density of 1×106/cm2, followed by removing CD45+, GlyA+ and CD34+ cells using negative separation and purifying using adherence method. Flk-1+ MSCs were obtained following isolated and expanded from bone marrow of aborted fetus. Peripheral blood mononuclear cells were isolated with gradient centrifugation using lymphocyte isolation solution, and they were used for mixed lymphocyte culture and mitogen-stimulated lymphocyte proliferation experiments. MAIN OUTCOME MEASURES: Flow cytometry was used to identify the immunological phenotypes. Inductors of osteogenesis, adipogenesis, chondrogenesis and endotheliogenesis were used to determine the potential of differentiation. After osteogenic differentiation or interferon-γ pretreatment, the expression of cell surface antigen, the expression of lymphocyte proliferation and activation antigen, CD60 and CD25, and the levels of interleukin-10 and transforming growth factor-β in supernatant were all detected. RESULTS: Under light microscope, bone marrow-derived MSCs grew in the fibroblast-like morphology. Flow cytometry showed a high level expression of Flk-1, CD29, CD44 and CD105 on the surface of MSCs, but no expression of CD34 and CD45. MSCs could be induced to differentiate into osteoblasts, adipocytes, chondrocytes and endotheliocytes in vitro. They were also shown to express low levels of MHC-Ⅰ molecules, but lacked expression of MHC-Ⅱ, and osteogenic differentiated MSCs increased their MHC-Ⅰ levels, and interferon-γ upregulated the MHC-Ⅱ expression. Bone marrow-derived Flk-1+ MSCs after 7 days of osteogenic differentiation or 48 hours of interferon-γ pretreatment still retained low immunogenicity but had stronger immunoregulatory capacity compared with undifferentiated MSCs (t=2.57, P < 0.05), further inhibiting the expression of CD69 and CD25. ELISA detection demonstrated a higher secretion of interleukin-10 in the supernatant (t=2.66, P < 0.05), and similar production of transforming growth factor-β were also detected after osteogenic differentiation, but significantly enhanced after the interferon-γ pretreatment. CONCLUSION: Bone marrow-derived Flk-1+ MSCs after osteogenic differentiation or interferon-γ pretreatment still maintain low immunogenicity, and their immunoregulatory activities are also further enhanced.